GlassScriptPhysician profile
Kate Xie
NPI 1124415187
$7,113.20
in general payments reported to CMS, 2019-2025
26 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $200 · 2021: $588 · 2022: $238 · 2023: $468 · 2024: $3,454 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,178 · Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,177.50 |
| Food and Beverage | $2,176.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,811.12 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Alcon Vision LLC | $593.03 | 2019-2025 | Clareon, Tryptyr, Unity |
| Rxsight INC | $592.27 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Dompe US, INC. | $476.22 | 2021-2025 | Oxervate |
| Glaukos Corporation | $309.76 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished), Istent Infinite |
| Ivantis, INC | $280.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $232.27 | 2019 | |
| New World Medical,INC. | $202.76 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
| Tarsus Pharmaceuticals, INC. | $188.65 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $175.87 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $166.33 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $163.72 | 2023-2025 | Stellaris, Envista Envy Iol |
| Kala Pharmaceuticals, INC. | $124.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.53 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $112.87 | 2024 | Catalys System, Veritas Vision System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $112.64 | 2023 | Syfovre |
| Biotissue Holdings INC. | $111.16 | 2023 | |
| Oyster Point Pharma, INC. | $98.57 | 2024-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $66.82 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $47.24 | 2023 | Artevo 800 |
| Abbvie INC. | $33.33 | 2024 | |
| Horizon Therapeutics Plc | $21.33 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.09 | 2025 | Acthar |
| Thea Pharma INC. | $18.98 | 2023 | |
| Aerie Pharmaceuticals, INC. | $16.71 | 2021 | |
| Shire North American Group INC | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.